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ABSTRACT: 
This review summarises current knowledge on the pulmonary manifestations of primary antibody 
deficiency (PAD) syndromes in adults.  We describe the major PAD syndromes, with a particular 
focus on Common Variable Immunodeficiency (CVID).  Respiratory infection is a common presenting 
feature of PAD syndromes, and respiratory complications are frequent and responsible for much of 
the morbidity and mortality.  Respiratory complications include acute infections, the sequelae of 
infection such as bronchiectasis, non-infectious immune-mediated manifestations - notably the 
development of granulomatous-interstitial lung disease (GLILD) in CVID - and an increased risk of 
lymphoma.  Although minor abnormalities are detectable in the lung on CT scanning in the majority 
of patients with CVID, not all go on to develop lung complications.  Mechanisms relating to the 
maintenance of lung health versus lung disease, and the development of bronchiectasis versus 
immune-mediated complications are now being dissected.  We review current investigation, 
treatment and management strategies, and include key research questions, relating to both 
infectious and non-infectious complications of PAD in the lung. 
 
KEY MESSAGES: 
1.  There are a wide spectrum of primary antibody deficiency (PAD) syndromes, reflecting the 
complexity of antibody reflection. 
2.  Respiratory infection is a common presenting feature of PAD, and respiratory clinicians should be 
alert to this. 
3.  Respiratory complications are also important in PAD – the focus of this review.  These drive 
morbidity and mortality. 
4.  Respiratory complications can be considered as acute infections, the consequences of infection 
(such as bronchiectasis), immune mediated (notably granulomatous-interstitial lung disease, GLILD) 
in Common Variable Immunodeficiency (CVID) and other, such as an increased risk of lymphoma. 
5.  The pathways determining the development of different lung complications are now being 
defined. 
6.  Acute infections require prompt treatment, and use of antibiotic prophylaxis is recommended in 
PAD. 
7.  The treatment of bronchiectasis in PAD is not different from the management of bronchiectasis 
from any other cause, with the exception of immunoglobulin replacement. 
8.  The definition, investigation, treatment and management of GLILD and other interstitial diseases 
in PAD remains poorly defined. 
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Introduction 
This review summarises current knowledge on the pulmonary manifestations of primary antibody 
deficiency (PAD) syndromes in adults, with a focus on Common Variable Immunodeficiency (CVID), 
which is the most clinically significant PAD adult physicians are likely to encounter, and also the most 
well described.  We will not consider PAD in children, upper airway (sino-nasal) manifestations of 
adult PAD, or lung disease in acquired antibody deficiency. 
 
Search Strategy and Selection Criteria 
A comprehensive literature review was conducted with support from the Clinical Effectiveness 
Enquiry Service at Royal Free London NHS Foundation Trust.  MEDLINE and EMBASE were searched 
using text-words and subject headings relating to primary immune (antibody) deficiency syndromes, 
and lung diseases.  The search strategy is provided in the supplementary appendix.  The search was 
restricted to English language publications, and after removal of duplicates 2360 articles remained.  
The titles and where necessary abstracts were screened by one author (JRH) for suitability for 
inclusion.  Additional citations were generated by examining the reference lists from the selected 
papers. 
 
The Spectrum of PAD Syndromes 
The production of specific antibodies targeted against pathogens is a key task for the mammalian 
immune system, and lack of a sufficient provision is the commonest immune defect seen in humans.  
A selective defect in IgA production is seen in 1 in 600 healthy blood donors[1] and a lack of IgG 
production has a prevalence of about 1 in 25000 individuals[2]. 
There are various mechanisms which may result in PAD, summarised below and illustrated in Figure 
1.  Specific antibodies (immunoglobulins) are produced by memory B-cells and plasma cells (which 
derive from B-cells), thus the lack of B-cells, as seen in patients with in-born errors of B-cell 
development (e.g. following mutations in the X chromosomal Bruton’s tyrosin kinase, Btk), will lead 
to agammaglobulinaemia.  Other patients (with B-cells) may be able to produce IgM as a first line 
response to antigenic challenge, but are not then able to isotype switch to IgG or IgA because of 
genetic defects in the class switch recombination machinery.  These patients are classified as “hyper 
IgM-”, or having a class switch recombination defect.  Others patients with B-cells are not capable of 
producing sufficient immunoglobulins to sustainably reach sufficient serum levels.  This large group 
of patients are classified as Common Variable Immunodeficiency (CVID): “common” as this defect is 
one of the commoner immune defects in humans and patients have relatively ‘similar’ (common) 
defects in baseline laboratory investigations, and “variable” as the clinical presentation is 
heterogeneous (which is discussed further below).  A further group of patients are not capable of 
producing a sufficient amount of one of the IgG subclasses.  In humans, deficiency of IgG1 (mostly 
directed against protein antigens) and IgG2 (directed against polysaccharide antigens) are clinically 
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relevant.  Finally, there are patients who are able to produce immunoglobulins, but these are not 
specific enough to eliminate (neutralise) the targeted pathogen.  These are called specific antibody 
deficiencies (SPAD).  This failure most frequently concerns the polysaccharides present in the 
capsule of encapsulated bacteria such as Pneumococcus and Haemophilus influenzae, highly 
relevant pathogens in respiratory diseases.  Antibodies are needed to opsonise capsulated bacteria 
thus activating the complement system.  This explains why in antibody-deficient patients respiratory 
infections are prevalent, and pose a clinical challenge.  Further details about these sub-groups are 
provided in the sections below. 
 
FIGURE 1: A summary of B-cell development, with reference to PAD disease pathogenesis.  
 
 
HYPER IgM SYNDROMES 
Class switch recombination (CSR) syndromes (hyper-IgM syndromes) can be caused either by an 
absence of sufficient B-cell co-stimulation such as the lack of CD40:CD40-ligand interaction, or by a 
defect in the CSR machinery, for example due to mutations in AID (Activation-induced cytidine 
deaminase, UNG (uracil DNA glycosylase), or INO80 and others.  CSR syndromes are characterised by 
normal or elevated levels of IgM but low IgG and IgA, and therefore susceptibility to respiratory 
infection[3]. 
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COMMON VARIABLE IMMUNODEFICIENCY DISORDERS (CVID) 
CVID, the most clinically significant PAD, forms part of a heterogeneous group of antibody disorders.  
Its prevalence is estimated to be 1:25-50000, affecting males and females equally.  Recurrent 
bacterial infections, commonly of a sino-pulmonary origin are the hallmark feature of this condition.  
Known complications include cytopaenias, autoimmunity, granuloma-formation affecting numerous 
organs (most commonly the lungs as discussed further below, and liver), splenomegaly, gastro-
intestinal tract involvement and lymphoproliferative disorders.  Multi-organ involvement is often 
seen, with end organ damage.  Though primarily a B-cell disorder, T-cell abnormalities may also 
occur in CVID. 
Symptoms of CVID can occur at any age, though tend to peak in early childhood, late adolescence 
and in the third and fourth decades.  The high variability in clinical features seen in CVID may result 
in a delay in diagnosis.  It has been reported that the delay from the onset of initial symptoms to 
formal diagnosis averages around five years in western countries[2] with a delay in initiating 
appropriate management. 
A low IgG level with a low IgA and/or IgM level combined with a poor vaccination response to a 
polysaccharide based vaccination should always raise suspicion of a diagnosis of CVID. The clinical 
criteria for a probable diagnosis of CVID as per the Registry Working Party of the European Society of 
Immunodeficiency[4] (ESID) are listed in Table 1.  
 
TABLE 1: ESID registry criteria for a probable diagnosis of CVID [4]. 
At least one of the following:  
• increased susceptibility to infection  
• autoimmune manifestations  
• granulomatous disease  
• unexplained polyclonal lymphoproliferation  
• affected family member with antibody deficiency  
AND marked decrease of IgG and marked decrease of IgA ,with or without low IgM levels (measured 
at least twice; <2SD of the normal levels for their age);  
AND at least one of the following:  
• poor antibody response to vaccines (and/or absent isohaemagglutinins); i.e. absence of protective 
levels despite vaccination where defined  
• low switched memory B cells (<70% of age-related normal value)  
AND secondary causes of hypogammaglobulinaemia have been excluded 
AND diagnosis is established after the 4th year of life (but symptoms may be present before)  
AND no evidence of profound T-cell deficiency 
 
X-LINKED AGGAMAGLOBULINAEMIA (XLA): 
As an X-linked disorder, XLA occurs almost exclusively in males.  A defect in the maturation of 
antibody-producing B-cells results in absent levels across all classes of immunoglobulins.  Most 
patients are diagnosed pre-school, once protective maternal antibodies have waned.  A later 
diagnosis has been reported in those with a negative family history, at an average age of 5.4 years 
compared to 2.6 years in those with a positive family history[5].  Infection with encapsulated 
organisms such as Streptococcus pneumoniae and Haemophilus influenzae are common.  Sino-
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pulmonary infections, most often otitis, are the most frequent presentation.  Other infections that 
may occur include conjunctivitis, septic arthritis, osteomyelitis, and enteroviral infection manifesting 
as diarrhoea and encephalitis.  Agammaglobulinaemia may also be seen as an autosomal recessive 
condition. 
 
SELECTIVE IgA DEFICIENCY 
Dimeric IgA2 is the most abundant antibody in mucosal secretions and selective IgA deficiency 
(sIgAD) is the most common primary immunodeficiency.  Although the prevalence of sIgAD is 1 in 
600 in Caucasians[1], less than 10% of subjects have clinical symptoms, suggesting the presence of 
compensatory mechanisms at the mucosal surface.  There is evidence that patients with sIgAD are at 
increased risk of both upper and lower respiratory tract, and gastro-intestinal infections[6]. 
 
IMMUNOGLOBULIN SUB-CLASS DEFICIENCY 
IgG is the predominant antibody in the circulation, and composed of four sub-classes each with 
structural differences that confer functional variation.  IgG subclass deficiency may occur in isolation 
or in combination with deficiency of other IgG subclass or immunoglobulin isotypes.  IgG2 deficiency 
predominates in childhood.  IgG4 is generally present in very low concentrations and absent in about 
8% of Caucasians.  Hence deficiency in this alone is not clinically significant.  IgG1 and IgG2 subclass 
deficiencies present in a similar manner to other PADs with recurrent upper and lower respiratory 
tract infections, sinusitis and otitis media, and an increased vulnerability to invasive infection with 
encapsulated organisms.  The nature of the pathogen susceptibility may indicate the subclass 
deficiency: for instance, those particularly lacking IgG2-polysaccaride-specific antibodies lack an 
important protective mechanism against encapsulated organisms such as Streptococcus pneumonia 
and encapsulated forms of Haemophilus influenzae. 
 
SPECIFIC ANTIBIODY DEFICIENCY 
The diagnosis of Specific Antibody Deficiency (SPAD) arises in those with normal total 
immunoglobulin levels but an impaired response to,  for example, polysaccharide antigens, detected 
through the use of polysaccharide test vaccinations such as Pneumovax-23.  An adequate 
vaccination response is usually one that is 4x greater than the baseline antibody level.   To exclude 
SPAD fully, we measure both the overall Pneumococcal titre as well as serotype specific 
pneumococcal antibody levels to 13 serotypes, both pre and post vaccination.  Impaired responses 
are present in children below the age of two years, who still have an immature immune response to 
encapsulated bacteria.  However, healthy children will grow out of this and only if they do not can 
SPAD be diagnosed.  Other components of the immune system are usually intact and therefore 
adults present with recurrent upper and lower respiratory tract infections, but often no other organ 
involvement. 
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GOOD’S SYNDROME 
The presence of a thymoma with associated hypogammaglobulinaemia comprises Good’s syndrome.  
Hypogammaglobulinaemia is seen in up to 10% of patients with a thymoma.  The clinical picture and 
laboratory investigations are variable but patients essentially present in a similar way to other PAD 
with an increased burden of bacterial infections with encapsulated organisms, but also opportunistic 
viral and fungal infections.  Urinary tract infections, skin infections, diarrhoea and autoimmunity 
have all been described.  Associated pathogens include cytomegalovirus and herpes simplex, 
candida, and Pneumocystis carinii.    
 
RECENT MUTATIONS DESCRIBED IN PAD: 
Over the past few years, a number of specific mutations have been identified in a proportion of 
patients with PAD, some of which may predispose to specific lung manifestations. 
APDS.  The recently described Activated PI3K-δ syndrome (APDS)[7 - 11] is a monogenetic autosomal 
dominant defect that leads to the activation of lymphocytes resulting in uncontrolled 
lymphoproliferation.  This is associated with impaired vaccine responses, reduced serum IgG2 and 
recurrent respiratory infection with airway damage.  In the lungs, the expanded lymphoid tissue, 
(including but not limited to the lymph nodes) compresses the bronchi, leading to characteristic 
radiologic and bronchoscopic appearances.  These lymphoid aggregates may result in post-stenotic 
pneumonia.  We will not further consider this entity. 
CTLA-4 deficiency.  CTLA-4 deficiency is a recently described autosomal dominant immune 
dysregulation syndrome characterised by an activated T-cell compartment[12,13].  As regulatory T-cells 
in this condition fail to exert their immune-regulatory effect, auto-aggressive immune cell 
infiltrations attack the lungs and often lead to granulomatous lymphocytic interstitial lung disease, 
which is described further below.  
 
Early recognition and diagnosis of PAD is vital.  We suggest that all patients with underlying 
structural lung disease should have baseline immunoglobulin levels measured at least once, 
including IgG, IgA and IgM, to exclude PAD.  If clinical suspicion for PAD remains, referral to an 
Immunologist should be sought for more specialist investigations.  Importantly, this is not reflected 
in national and international guidelines across the spectrum of lung disease. 
 
 
Lung Disease in PAD 
The respiratory manifestations of PAD follow two basic pathophysiological mechanisms, i) the 
sequelae of recurrent acute infections and ii) immune-mediated pathology.  Hence, two distinct 
patterns of chronic lung disease develop: bronchiectasis and interstitial disease.  These may be 
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readily distinguished using computed tomography (CT), as illustrated in Figure 2.  It is now apparent 
that the presence of these two conditions is associated with different immune profiles, at least when 
examined in retrospective studies.  Whether such parameters predict the development of future 
lung complications at the time of diagnosis remains to be assessed, but would be a major clinical 
development.  Interstitial disease, for example, has been associated with altered CD4:CD8 T-cell 
proportionality (ratio increased), elevated IgM, a history of autoimmune haemolytic anaemia or 
immune thrombocytopenic purpura and tends to occur at a younger age.  In contrast, bronchiectasis 
tended to affect an older age group, and is associated with a history of pneumonia and a CD4+ T-cell 
count lower than 700 cells/μl[14].  This is summarised in Figure 3. 
 
FIGURE 2: Typical lung-window CT findings in bronchiectasis (left, A) and interstitial lung disease 
(right, B), both in patients with underlying antibody deficiency.  Bronchiectasis is seen as bronchial 
wall thickening, and dilatation of the bronchus in relation to the accompanying vessel.  The 
interstitial scan shows multiple peri-bronchial nodules and ground-glass change.  Fibrosis is seen in 
patients with more advanced interstitial disease. 
A 
 
B 
 
 
FIGURE 3: Hypothetical scheme outlining pathways to the development of lung disease in PAD.  Ig= 
immunoglobulin; GLILD= granulomatous interstitial lung disease; MBL= mannose binding lectin. 
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The detection of lung involvement in PAD is important because of effects on quality of life[15,16] and 
mortality[17].  In a seminal study, mortality in CVID has been linked to both structural and functional 
lung impairment[17].  A diagnosis of structural lung disease included interstitial changes on CT, 
granulomatous or lymphocytic infiltrates confirmed on lung biopsy, bronchiectasis, or a combination 
of these.  Functional lung disease included restrictive or obstructive lung pathology, reduced 
diffusion capacity, and/or reduced oxygen saturation. 
Classically bronchiectasis, at least when severe, is associated with airflow obstruction (decreased 
FEV1/VC ratio) whilst interstitial change is typically associated with restrictive abnormalities on 
pulmonary function, including impairment in gas transfer (decrease in DLCO)
 [18].  When spirometry is 
normal, early abnormality may be detectable by changes in mid-expiratory flows. 
The prevalence of lung disease is lower in XLA than CVID, likely reflecting both earlier diagnosis and 
the additional immune dysregulation seen in CVID[19]. 
It is known that over 90% of patients with CVID have abnormalities present on CT scan of the 
lungs[20], typically mild and present even in patients who are asymptomatic[18].  We recommend a 
baseline CT chest at diagnosis of PAD to identify respiratory complications early in the illness, 
allowing prompt treatment and providing a baseline from which to assess future change.   In those 
who are asymptomatic, and in the absence of other biological markers, this results in the clinical 
problem of identifying which patients will go on to develop progressive lung disease, mandating 
repeat CT assessments (in our practice five yearly to limit lifetime radiation exposure with repeated 
scanning, and with annual lung function screening).  Whilst certain cell populations (e.g. memory B-
cells) may be absent or reduced in those with chronic lung disease[21], it is not known if the 
association with chronic lung disease is cause or effect.  In those with symptoms, the commonest 
problems are recurrent infections, at a median frequency of 2.5 events per year, and productive 
cough[22]. 
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Current assessment of patients with lung involvement requires serial lung function testing, six 
monthly to yearly depending on severity, and repeat imaging, as lung involvement can progress 
despite immunoglobulin replacement[23].  Repeated exposure to ionising radiation is a concern, 
particularly in patients whose genetic defect affects DNA recombination and DNA repair, leading to 
radio-sensitivity.  Protocols should therefore minimise the radiation exposure.  MRI has been 
explored as a tool to replace CT[24], but scan resolution remains a challenge as illustrated in Figure 4.  
However, MR sequences may give additional functional information to that provided by CT, for 
example regarding the cellularity of pulmonary nodules. 
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FIGURE 4: A comparison of MR (A, left) and CT images (B, right) from a patient with CVID and 
interstitial lung disease.  Note that the MR provides less special resolution, but on these T2-
weighted images the presence of oedema (high signal) within some nodules becomes apparent.  
CT shows bilateral ground-glass and more dense nodular infiltration, only some of which is visible 
on MRI. 
A 
 
B 
 
 
Little is known about rates of lung function decline in PAD, or the factors affecting this.  In a small 
study of 37 patients over an average period of 7.6 years[25], the average decline in FEV1 was 
45ml/year, greater than would be expected in a normal population (typically 30 ml/year), and similar 
to that expected in a susceptible smoker.  Decline was more rapid in patients diagnosed at a younger 
age and was more rapid in XLA than CVID patients (65 vs. 36ml/year).  Decline was reduced in 
patients on higher doses of immunoglobulin replacement (irrespective of trough level).  The 
relationship with antibiotic use and infection frequency remains to be defined[26].  The concept that 
immunoglobulin replacement can be used to reduce lung function decline requires further 
confirmation. 
It is important to draw a distinction between disease severity which can be assessed using cross-
sectional measures such as a single lung function test or CT, and the disease activity, or speed of 
progression of lung disease.  We reported in a small study in patients with PAD that the rate of FEV1 
decline (but not absolute FEV1 or extent of disease on CT) was directly proportional to the systemic 
acute phase response (and that systemic inflammation was related to that in the airway)[16]. 
 
 
Acute Infections 
Acute infections contribute significantly to the costs of care in patients with PAD[27].  It is clear that 
immunoglobulin replacement is effective in reducing the risk of infection, including pneumonia, 
otitis media, and systemic infections in patients with XLA, hyper-IgM and CVID[28-30].  Despite 
immunoglobulin replacement, susceptibility to infection remains variable[31] and may relate to low 
IgA concentration.  Trough levels relate to infection susceptibility in meta-analysis[30].  Over a five 
year period in 201 patients, 21% of CVID patients and 24% of XLA patients were infection free.  A 
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higher steady-state IgG in subcutaneous replacement is also associated with fewer acute 
infections[32].  Both Intravenous and subcutaneous immunoglobulin replacement have been shown 
to be equally effective routes of administration in reducing infection burden.  There are no specific 
guidelines for an ‘adequate’ trough level though generally the aim is to be above the lower limit of 
the normal IgG range.  It has been proposed that rather than a particular trough level, the number of 
breakthrough infections should determine the immunoglobulin dose for each individual patient[29]. 
With regard to the causative pathogens, bacterial infections are most important, typically with 
Streptococcus, Haemophilus and Staphylococcus, at least when employing culture-based detection.  
Viral infections, including rhinovirus infection, may be both more frequent and more prolonged in 
PAD[33].  Pathogens that are considered ‘opportunistic’ in the context of conditions such as HIV, for 
example Pneumocystis and CMV, do not appear common in the context of PAD lung disease[34.  This 
likely reflects the relative preservation of adequate T-cell function in many patients with PAD. 
Acute infection should be managed as for guidance in patients without underlying PAD, but 
treatment may need to be prolonged for 10 to 14 days in patients with established bronchiectasis. 
Evidence is scarce on appropriate antibiotic prophylaxis and its use, in PAD.  In our clinical 
experience, similar to other centres nationwide, antibiotic prophylaxis has been associated with a 
substantially reduced infection burden.   Our practice is to offer antibiotic prophylaxis to all patients 
with PAD and recurrent infections, especially when there are known structural lung changes.   
Preventing infections is of key importance in reducing long term morbidity.  We do not routinely use 
antifungal prophylaxis , in the absence of data that fungal pathogens are a common cause of 
infection in  our cohort of CVID patients.  In those with evidence of significantly reduced T cell counts 
with or without T cell dysfunction, we prefer co-trimaxazole as antibiotic prophylaxis to cover both 
bacterial and fungal organisms.    
 
 
Bronchiectasis in PAD 
Clinically significant bronchiectasis is defined as permanent abnormal dilatation of the airways in 
conjunction with persistent or recurrent bronchial sepsis[35].  The clinical picture is therefore one of 
chronic productive cough, susceptibility to recurrent exacerbations, and breathlessness in those with 
more extensive disease. 
Despite the importance of detecting primary immunodeficiency as a (treatable) cause of 
bronchiectasis, a UK national audit reported that only 68% of patients with bronchiectasis had 
documented serum immunoglobulin assay[36]. 
The prevalence of bronchiectasis in CVID, 23% across a European cohort of 902 subjects, varies 
considerably by centre[37].  In part this reflects the difficulty in differentiating minor degrees of 
bronchiectasis from healthy lung, but even in the absence of bronchiectasis there may be airway 
wall thickening, with secondary atelectasis and gas-trapping visible on CT[38]. 
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We have previously reported that health-status in patients with PAD and bronchiectasis is largely 
driven by the respiratory involvement, and related to the degree of airflow obstruction, 
breathlessness, and respiratory infection frequency[16].  Thus, preventing infections might be 
expected to maintain or improve health-status, and there is now evidence for strategies such as 
macrolide antibiotics to achieve this in patients with bronchiectasis (though some trials excluded 
PAD populations) [39-41]. 
As not all patients with PAD develop bronchiectasis, it is clear that co-factors must be important and 
it has been suggested that additional deficiency of mannose-binding lectin (MBL), a protein 
component of the complement pathway, may be one such variable[42].  Low IgA has also been 
associated with the development of bronchiectasis[31], as has activity of the neonatal Fc receptor 
(FcRn) activity[43]. 
The management of bronchiectasis in PAD is not different from the management of bronchiectasis 
from any other cause[39], with correction of the underlying defect (in this case optimal 
immunoglobulin replacement), sputum clearance training from a respiratory physiotherapist and 
prevention of further infection which usually involves prophylactic antibiotics in patients with PAD.  
There is a paucity of data about antibiotic choice, with the greatest evidence for macrolides[39-41] 
though with the caveat that evidence specifically in PAD is poor[44].  Whether the beneficial effect of 
macrolides is due to a classical antibiotic effect remains to be clarified and anti-inflammatory action 
may also be relevant.  There is a general consensus[35] to avoid ciprofloxacin prophylaxis given the 
utility of this drug in treating Pseudomonas.  Patients with PAD may not make appropriate vaccine 
responses to the influenza and Pneumococcal vaccines that are recommended as part of usual 
bronchiectasis care. 
There remains something of a paradox in the concept that IgA provides most mucosal defence, yet 
IgA deficiency tends to result in less severe lung disease than that associated with IgG deficiency, 
and replacement of IgG into the systemic circulation is able to reduce the frequency of respiratory 
infections[17].  This may be because whilst IgA is mostly present in the upper airways, IgG is the most 
prevalent immunoglobulin in the alveolar space. 
Whilst primarily prescribed to reduce the incidence of acute infection, there is data from a small 
study in thirteen patients[45] that immunoglobulin replacement may be associated with beneficial 
effects on airway inflammation, including a reduction in inflammatory cell count, and increased 
mucus transportability. 
Studies using culture and PCR have demonstrated the presence of potentially pathogenic bacteria 
and viruses from the lungs of patients with PAD even when clinically stable[47].  Haemophilus 
influenza is the commonest pathogen identified by culture[22].  However, our understanding of the 
lung microbiome has been transformed over recent years, such that we now understand that the 
differences between health and disease, and stable and exacerbated states are associated with 
differences in bacterial populations[46].  While research is underway, there are no published data 
exploring how the respiratory microbiome may be altered in patients with underlying PAD or, 
indeed, whether changes in the microbiome may predispose to rather than result from specific types 
of lung disease. 
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Interstitial Lung Disease in PAD 
Any interstitial lung disease may be seen in association with PAD, but the most common, the most 
heavily researched, and the one most closely associated with poor clinical outcomes is currently 
considered clinically as an entity called granulomatous-interstitial lung disease (GLILD).  This term, 
helpful to clinicians, is less widely accepted by pathologists and requires the development of a 
precise clinico-pathologico-radiological definition comparable to other ILD.  Radiologically, the 
typical pattern of interstitial lung disease in PAD is a generalised diffuse reticular change, often with 
ground-glass appearance, and a lower lobe predominance.  In one report, large, ill-defined 
bronchocentric nodules or small randomly distributed nodules were found in 50%, invariably in 
association with reticular change and 38% had thoracic lymphadenopathy[48].  This is illustrated in 
Figure 2. 
Histologically, this condition is characterised by both granulomatous, and lymphoproliferative 
features including non-necrotising granuloma, lymphocytic interstitial pneumonitis and follicular 
bronchiolitis (Figure 5).  Recently, the lymphoid hyperplasia has been carefully characterised and 
found to contain a variable preponderance of B- and T-cells (more commonly T-cell predominant), 
organised into distinct zones, with evidence of active cellular proliferation[49]. 
 
FIGURE 5: Histology of GLILD demonstrating a polymorphous infiltrate of lymphocytes, plasma 
cells and macrophages. 
 
 
GLILD is perhaps best considered as the pulmonary manifestation of a systemic syndrome associated 
with autoimmune cytopaenia, splenomegaly, enteritis and adenopathy.  GLILD is not seen in XLA, 
suggesting that T-cell dysfunction is central to the pathogenesis, though the detailed mechanisms 
remain poorly understood.  Various studies have examined the role of viruses such as herpes viruses 
in driving lymphocyte proliferation without consistent results. 
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Clinically, patients experience cough and breathlessness.  Impairment in gas transfer appears to be 
the most frequent abnormality on lung function testing[50].  As the natural history of GLILD is not well 
documented in PAD patients, observational studies such as STILPAD[51] are on-going to further 
examine this complication. 
Our approach, summarised as Figure 6, is to confirm the diagnosis of GLILD at surgical (video-
assisted thoracic surgery, VATS) lung biopsy.  This is not a trivial procedure, but the relative 
preponderance of different cell populations may then be used to guide second-line therapy.  Direct 
evidence in support of this approach remains limited[49].  The differential diagnosis includes 
infection, other ILD, and lymphoma.  We perform broncho-alveolar lavage, prior to biopsy, to 
exclude infection.  It has been suggested that GLILD may be associated with a BAL lymphocytosis 
(>20%) in the majority of patients[52,53], but whether further analysis of cells retrieved at BAL is able 
to avoid surgical biopsy has yet to be properly examined.  The CD4/CD8 preponderance has varied 
between studies, and a higher ratio has been associated with a more favourable prognosis in terms 
of lung function decline in one study[53], but not in another[54].  It is recognised that abnormalities 
present in blood lymphocyte populations in CVID may also be present in BAL[55], but in general there 
is a paucity of data on lung lymphocyte populations in CVID 
 
FIGURE 6: An approach to the diagnosis and management of GLILD in CVID. 
 
One study[53] included an assessment with trans-bronchial biopsy but this was not adequate to make 
a firm diagnosis in over 2/3 of patients. 
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Disease progression can be seen in patients on immunoglobulin replacement[23]  There are no 
appropriate studies examining whether immunoglobulin optimisation alone can improve lung 
function in GLILD.  High dose corticosteroids are often used as first-line therapy, although the 
evidence is weak[50,56], and a complete response may require combination therapies since response 
to steroids may be absent in around half of patients[50].  Based on our clinical experience we  start at 
1mg/kg/day until there is maximal improvement in lung function and radiology and then wean 
(Figure 6).  When abnormalities are visible on plain radiography, this can be used to monitor therapy 
in preference to CT.  Patients are monitored for CD4 lymphopenia secondary to corticosteroid 
immunosuppression and prophylaxis for Pneumocystis considered if the CD4 count falls below 
200x109/l.   There is no specific evidence that this is beneficial in CVID patients but there is increasing 
evidence of this having a protective effect in non HIV immunocompromised patients[57] 
Case reports suggest rituximab can improve pulmonary function[49], and has been used in 
conjunction with azathioprine (targeting T-cells) resulting in resolution of spirometry and imaging 
abnormalities[58] in a small series.  Other T-cell agents that have been tried include ciclosporin[59] and 
abatacept.  Case reports exist for infliximab[60].  We have clinical experience using mycophenolate as 
second-line therapy. 
Bone-Marrow Transplant has been performed in selected patients with GLILD[61]. 
Although larger datasets are required, it is clear that GLILD is associated with reduced life 
expectancy in CVID[62].  There is little data on outcomes of lung transplantation, which has on 
occasion been successfully performed although reviews suggest outcomes may be variable[63], and 
granulomas have been reported to recur[22]. 
It is unusual for patients with underlying PAD and histologically confirmed GLILD to display no 
symptoms.  In the rare instances where this is the case, treatment should still be considered to 
prevent further end organ damage. 
 
 
Other 
Organising pneumonia (previously referred to as BOOP – bronchiolitis obliterans organising 
pneumonia) has been reported in association with CVID[64] (although therefore would not be 
considered “cryptogenic”).  The diagnosis would be established at biopsy and organising pneumonia 
is also treated in the first instance with systemic corticosteroids. 
Patients with CVID are at increased risk of lymphoma, typically B-cell NHL.  MALT lymphoma may 
occur in the lung[65] and should be considered in the differential diagnosis of GLILD.  The 
management of intra-pulmonary lymphoma is out with the scope of this review. 
 
Processes of Care 
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We advocate a shared care approach, ideally with joint respiratory-immunology clinics for patients 
with respiratory complications of PAD.  This will facilitate access to a multi-professional team 
including radiologists, pathologists, and respiratory clinicians and respiratory physiotherapists in 
addition to the immunodeficiency team.  Historically, there has been a delay both in patients with 
immunodeficiency seeing chest specialists (and chest specialists making the diagnosis of PAD in 
patients first presenting with respiratory pathology)[22]. 
 
Key Research Questions 
It will be apparent from the above that key research questions remain regarding the optimal 
monitoring regime for lung disease in patients with PAD, and appropriate strategies for diagnosis 
and management.  We propose the following key research priorities: 
How can we best identify which PAD patients will retain healthy lungs, and which will develop 
bronchiectasis or GLILD? 
What is the best prophylactic antibiotic management for patients with PAD and bronchiectasis?  
What is the optimal management for patients with GLILD?  
Is immunosuppression the only treatment for GLILD, and if so, which is the optimal 
immunosuppressive regimen? 
How frequently should lung involvement be monitored by CT and lung function and in which 
patients is follow-up with MRI acceptable? 
 
 
Summary 
Respiratory manifestations of PAD are important because of the impact on morbidity and mortality.  
Bronchiectasis is the most common manifestation, with GLILD occurring in perhaps 15% of patients 
with CVID.  The former should be managed according to standard guidelines, but evidence for 
effective diagnosis, monitoring and therapy of GLILD are lacking and remains an area of research 
priority. 
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Appendix: Search Strategy 
Database: Ovid MEDLINE(R) Daily Update <November 19, 2014>, Ovid OLDMEDLINE(R) <1946 to 
1965>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to 
Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     ((primary adj2 (antibody or immun*) adj2 deficienc*) or primary immunodeficienc*).ti,ab. (3325) 
2     Immunologic Deficiency Syndromes/ (13104) 
3     Common Variable Immunodeficiency/ (1592) 
4     (common adj4 variable adj4 (immunodeficien* or immune deficien* or immuno-deficien*)).ti,ab. 
(1941) 
5     CVID.ti,ab. (961) 
6     Agammaglobulinemia/ (5776) 
7     (hypogammaglobulin?emia* or agammaglobulin?emia*).ti,ab. (4462) 
8     XLA.ti,ab. (460) 
9     exp dysgammaglobulinemia/ (2961) 
10     dysgammaglobulinemia?.ti,ab. (218) 
11     Hyper IgM syndrome*.ti,ab. (394) 
12     (HIGM? or XHIGM?).ti,ab. (150) 
13     leukocyte-adhesion deficiency syndrome/ (405) 
14     leukocyte-adhesion deficiency.ti,ab. (486) 
15     phagocyte bactericidal dysfunction/ (605) 
16     granulomatous disease, chronic/ (2821) 
17     ((Bridges-Good or Quie or chronic granulomatous) adj (syndrome or disorder or disease)).ti,ab. 
(3081) 
18     job syndrome/ (555) 
19     ((hyper-IgE or hyperimmunoglobulinemia E or job or buckley) adj syndrome?).ti,ab. (508) 
20     exp severe combined immunodeficiency/ (2681) 
21     severe combined immunodeficienc*.ti,ab. (4271) 
22     wiskott-aldrich syndrome/ (1353) 
23     ((wiskott or Aldrich) adj syndrome).ti,ab. (1936) 
24     T-Lymphocytopenia, Idiopathic CD4-Positive/ (228) 
25     ((idiopathic or cd4?) adj2 (t-lymphocytop?enia? or lymphocytop?enia?)).ti,ab. (371) 
26     or/1-25 (35842) 
27     lung diseases/ (61262) 
28     Respiratory Tract Infections/ (32172) 
29     ((respiratory or lung) adj disease?).ti,ab. (56327) 
30     exp Lung Diseases, Interstitial/ (48024) 
31     exp Lung Diseases, Fungal/ (18385) 
32     exp lung diseases, obstructive/ (176859) 
33     exp Bronchiectasis/ (7757) 
34     bronch?ect*.ti,ab. (7358) 
35     exp pneumonia/ (77125) 
36     pneumonia.ti,ab. (84950) 
37     exp tuberculosis, pulmonary/ (68314) 
38     tuberculosis.ti,ab. (152812) 
39     Lung Abscess/ (4115) 
40     ((lung or pulmonary) adj abscess*).ti,ab. (2621) 
41     Pulmonary Fibrosis/ (16573) 
42     Plasma Cell Granuloma, Pulmonary/ (249) 
26 
 
43     ((pulmonary or lung*) adj2 ((inflammatory adj1 pseudotumo?r?) or (plasma cell adj1 
granuloma?))).ti,ab. (111) 
44     pulmonary fibros?s.ti,ab. (11613) 
45     or/27-44 (621902) 
46     26 and 45 (3514) 
47     limit 46 to animals (318) 
48     limit 47 to humans (148) 
49     47 not 48 (170) 
50     46 not 49 (3344) 
51     limit 50 to english language (2447) 
52     limit 51 to "all child (0 to 18 years)" (1364) 
53     limit 52 to "all adult (19 plus years)" (425) 
54     52 not 53 (939) 
55     51 not 54 (1508) 
 
Database: Embase <1980 to 2014 Week 47> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     ((respiratory or lung) adj disease?).ti,ab. (68861) 
2     lung disease/ or autoimmune lung disease/ or exp bronchiolitis/ or chronic lung disease/ or 
chronic obstructive lung disease/ or exp interstitial lung disease/ or exp lung fibrosis/ or lung 
granuloma/ or exp lung infection/ or lung nodule/ or lung pseudotumor/ or lung sarcoidosis/ or 
multiple pulmonary nodules/ or exp pneumonia/ or small airway disease/ (476839) 
3     exp bronchitis/ (46491) 
4     exp bronchiectasis/ (13121) 
5     bronch?ect*.ti,ab. (9042) 
6     pneumonia.ti,ab. (103966) 
7     tuberculosis.ti,ab. (151935) 
8     ((lung or pulmonary) adj abscess*).ti,ab. (2738) 
9     ((pulmonary or lung*) adj2 ((inflammatory adj1 pseudotumo?r?) or (plasma cell adj1 
granuloma?))).ti,ab. (131) 
10     pulmonary fibros?s.ti,ab. (14275) 
11     or/1-10 (646435) 
12     ((primary adj2 (antibody or immun*) adj2 deficienc*) or primary immunodeficienc*).ti,ab. 
(4834) 
13     (common adj4 variable adj4 (immunodeficien* or immune deficien* or immuno-
deficien*)).ti,ab. (2639) 
14     CVID.ti,ab. (1699) 
15     exp agammaglobulinemia/ or exp dysgammaglobulinemia/ (9569) 
16     (hypogammaglobulin?emia* or agammaglobulin?emia*).ti,ab. (5130) 
17     XLA.ti,ab. (606) 
18     dysgammaglobulinemia?.ti,ab. (204) 
19     Hyper IgM syndrome*.ti,ab. (487) 
20     (HIGM? or XHIGM?).ti,ab. (200) 
21     combined immunodeficiency/ or exp severe combined immunodeficiency/ or wiskott aldrich 
syndrome/ (9293) 
22     exp leukocyte adhesion deficiency/ (677) 
23     leukocyte-adhesion deficiency.ti,ab. (571) 
24     phagocyte dysfunction/ or chronic granulomatous disease/ or granulocytopenia/ or hyper ige 
syndrome/ (9273) 
27 
 
25     ((Bridges-Good or Quie or chronic granulomatous) adj (syndrome or disorder or disease)).ti,ab. 
(3431) 
26     ((hyper-IgE or hyperimmunoglobulinemia E or job or buckley) adj syndrome?).ti,ab. (744) 
27     severe combined immunodeficienc*.ti,ab. (4594) 
28     ((wiskott or Aldrich) adj syndrome).ti,ab. (2103) 
29     ((idiopathic or cd4?) adj2 (t-lymphocytop?enia? or lymphocytop?enia?)).ti,ab. (451) 
30     or/12-29 (37024) 
31     11 and 30 (4726) 
32     limit 31 to english language (4186) 
33     limit 32 to (embryo <first trimester> or infant <to one year> or child <unspecified age> or 
preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>) (1258) 
34     limit 33 to (adult <18 to 64 years> or aged <65+ years>) (371) 
35     33 not 34 (887) 
36     32 not 35 (3299) 
37     limit 36 to animals (165) 
38     36 not 37 (3134) 
39     limit 38 to conference abstract (774) 
40     38 not 39 (2360) 
 
 
